- HealthTech
- Tuesday, 09 Jun 2020
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
The new clinical manufacturing facility will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
This news follows WuXi Biologics' recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.
Related Industry Updates
Global Preimplantation Genetic Diagnosis Market 2021-2027: Industrial Output, Import & Export, Consumer Consumption and Forecast 2027
Apr 21, 2021
Europe Neurological Biomarkers Market Insights, Opportunity Analysis, Industry Shares And Forecast 2020-2027
Apr 01, 2021
Technology and Finding People to Work With It May Become a Major Challenge for Healthcare Organizations
Jan 10, 2020
Asia Pacific Anti-Viral Therapies Market To See Tremendous Rise during 2019-2027 wuith Top Companies Like Aurobindo Pharma Ltd, AbbVie, GlaxoSmithKline, AstraZeneca
Mar 31, 2021
Latest Report on Asia Pacific Dental X-Ray Market is projected to reach US$ 1,116.80 million by 2027| Business Market Insights
Jan 21, 2021
North America Microminiature Circular Connector Market Study: An Emerging Hint of Opportunity | Glenair, Ulti-Mate Connector, ITT, Hirose Electric
Oct 16, 2020
Animal Genetics Market to Eyewitness Massive Growth by 2026 | NEOGEN , HENDRIX GENETICS BV, Zoetis
Apr 26, 2021